1st Edition
Organ Specific Drug Delivery and Targeting to the Lungs
Organ Specific Drug Delivery and Targeting to the Lungs provides up to date information on the multidisciplinary field of particle engineering and drug delivery to the lungs, including advancements of nanotechnology. The text presents a unique, pragmatic focus with case studies, that help translate scientific understanding to practical implementation. In addition to highlighting the successful case studies, it also offers practical advice on watchouts, limitations, and ‘bookend’ boundaries involved in the stages of testing and development.
Additional Features Include:
- Provides an account of particle engineering, discovery, biology, development, and delivery in relation with the advancements of nanotechnology, unlike any previous book.
- Brings together the leading experts and researchers in the field to critically assess and discuss various topics influencing drug delivery.
- Highlights the interplay of different scientific disciplines and the balance of requirements that are critical to molecule and product design.
With the strategic focus on what matters during new product development, this book provides a guide to understanding and navigating new drug discovery and development for lung targets.
Chapter 01
Estimating Clinically Relevant Measures of Inhaled Pharmaceutical Aerosol Performance with Advanced In Vitro and In Silico Methods
Chapter 02
In Vitro Assessment of Drug Release, Dissolution, and Absorption in the Lung
Chapter 03
Lung-on-a-Chip and Lung Organoid Models
Chapter 04
Interaction between Inhalable Nanomedicines and Pulmonary Surfactant
Chapter 05
Particle engineering for pulmonary drug delivery
Chapter 06
Particle Architectonics for Pulmonary Drug Delivery
Chapter 07
Engineered Particles for Aerosolisation and Lung Deposition
Chapter 08
Recent advances in inhalable nanomedicine for lung cancer therapy
Chapter 09
Thin-Film Freeze-Drying Process for Versatile Particles for Inhalation Drug Delivery
Chapter 10
Nanoparticles as specific drug carriers
Chapter 11
Surface modification of micronized drug particles for aerosolization
Chapter 12
Spray Dried Particles for Inhalation
Chapter 13
Inhalation Aerosol Phospholipid Particles for Targeted Lung Delivery
Chapter 14
Nebulizers
Chapter 15
Protein and Peptide Delivery to the Lung via Inhalation
Chapter 16
Exosomes Based Drug Delivery for Lung Cancer Treatment
Biography
Ajit S. Narang works for the Department of Pharmaceutical Sciences at ORIC Pharmaceuticals, Inc., in South San Francisco, CA. His primary expertise is in oral drug delivery. He holds over 20 years of pharmaceutical industry experience in drug development. Prior to ORIC, Ajit has also worked for Genentech, Inc.; Bristol-Myers Squibb, Co.; Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan); and Morton Grove Pharmaceuticals (currently, Wockhardt USA). He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutical Sciences from the Banaras Hindu University, India, and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN. He currently serves as the Chair of Biopharmaceutics Technical Committee of the Product Quality Research Institute. His current research interests focus on new drug discovery research. He has been credited with several publications, patents, and books throughout his career; and has contributed to the development of several clinical and marketed drug products.
Ram I. Mahato is Professor and Chairman of the Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE. He was a professor at the University of Tennessee Health Science Center, Research Assistant Professor at the University of Utah, Senior Scientist at GeneMedicine, Inc., and as a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He received PhD in Drug Delivery from the University of Strathclyde, Great Britain and BS from China Pharmaceutical University, Nanjing. He has published 166 peer reviewed papers, 24 book chapters, holds 3 US patents, and has edited/written nine books and eleven journal issues (Total Google Citations= 13,060 and h-Index =67). He is an Associate Editor of the Journal of Neuroimmune Pharmacology, was a Feature Editor of the Pharmaceutical Research (2006-2013). He is a CRS and AAPS Fellow. He is applying sound principles in pharmaceutical sciences in the context of the latest advances in life and material sciences to solve challenging drug delivery problems in therapeutics. His areas of research include delivery and targeting of small molecules, miRNA and genes using novel polymeric and lipid carriers for treating cancer, liver fibrosis and diabetes.
